BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23499446)

  • 1. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency.
    Ternette N; Yang M; Laroyia M; Kitagawa M; O'Flaherty L; Wolhulter K; Igarashi K; Saito K; Kato K; Fischer R; Berquand A; Kessler BM; Lappin T; Frizzell N; Soga T; Adam J; Pollard PJ
    Cell Rep; 2013 Mar; 3(3):689-700. PubMed ID: 23499446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
    Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
    J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite.
    Perez M; Bak DW; Bergholtz SE; Crooks DR; Arimilli BS; Yang Y; Weerapana E; Linehan WM; Meier JL
    J Biol Chem; 2020 Sep; 295(39):13410-13418. PubMed ID: 32820045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase.
    Frezza C; Zheng L; Folger O; Rajagopalan KN; MacKenzie ED; Jerby L; Micaroni M; Chaneton B; Adam J; Hedley A; Kalna G; Tomlinson IP; Pollard PJ; Watson DG; Deberardinis RJ; Shlomi T; Ruppin E; Gottlieb E
    Nature; 2011 Aug; 477(7363):225-8. PubMed ID: 21849978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and "cryptic targets" of transcription factors.
    Ooi A; Furge KA
    Chin J Cancer; 2012 Sep; 31(9):413-20. PubMed ID: 22776233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
    Ooi A
    Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fumarate Hydratase Loss Causes Combined Respiratory Chain Defects.
    Tyrakis PA; Yurkovich ME; Sciacovelli M; Papachristou EK; Bridges HR; Gaude E; Schreiner A; D'Santos C; Hirst J; Hernandez-Fernaud J; Springett R; Griffiths JR; Frezza C
    Cell Rep; 2017 Oct; 21(4):1036-1047. PubMed ID: 29069586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
    Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
    Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.
    Linehan WM; Rouault TA
    Clin Cancer Res; 2013 Jul; 19(13):3345-52. PubMed ID: 23633457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).
    Chan E; Rabban JT; Mak J; Zaloudek C; Garg K
    Am J Surg Pathol; 2019 Sep; 43(9):1170-1179. PubMed ID: 31162287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma.
    Yang Y; Lane AN; Ricketts CJ; Sourbier C; Wei MH; Shuch B; Pike L; Wu M; Rouault TA; Boros LG; Fan TW; Linehan WM
    PLoS One; 2013; 8(8):e72179. PubMed ID: 23967283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
    Sourbier C; Ricketts CJ; Liao PJ; Matsumoto S; Wei D; Lang M; Railkar R; Yang Y; Wei MH; Agarwal P; Krishna M; Mitchell JB; Trepel JB; Neckers L; Linehan WM
    Sci Rep; 2019 Dec; 9(1):18409. PubMed ID: 31804603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
    Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
    Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.
    Ashrafian H; O'Flaherty L; Adam J; Steeples V; Chung YL; East P; Vanharanta S; Lehtonen H; Nye E; Hatipoglu E; Miranda M; Howarth K; Shukla D; Troy H; Griffiths J; Spencer-Dene B; Yusuf M; Volpi E; Maxwell PH; Stamp G; Poulsom R; Pugh CW; Costa B; Bardella C; Di Renzo MF; Kotlikoff MI; Launonen V; Aaltonen L; El-Bahrawy M; Tomlinson I; Pollard PJ
    Cancer Res; 2010 Nov; 70(22):9153-65. PubMed ID: 20978192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism.
    Bardella C; Olivero M; Lorenzato A; Geuna M; Adam J; O'Flaherty L; Rustin P; Tomlinson I; Pollard PJ; Di Renzo MF
    Mol Cell Biol; 2012 Aug; 32(15):3081-94. PubMed ID: 22645311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioorthogonal oncometabolite ligation.
    Briney CA; Najera S; Meier JL
    Methods Enzymol; 2019; 622():431-448. PubMed ID: 31155064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
    Tong WH; Sourbier C; Kovtunovych G; Jeong SY; Vira M; Ghosh M; Romero VV; Sougrat R; Vaulont S; Viollet B; Kim YS; Lee S; Trepel J; Srinivasan R; Bratslavsky G; Yang Y; Linehan WM; Rouault TA
    Cancer Cell; 2011 Sep; 20(3):315-27. PubMed ID: 21907923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
    Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
    Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia.
    Adam J; Yang M; Bauerschmidt C; Kitagawa M; O'Flaherty L; Maheswaran P; Özkan G; Sahgal N; Baban D; Kato K; Saito K; Iino K; Igarashi K; Stratford M; Pugh C; Tennant DA; Ludwig C; Davies B; Ratcliffe PJ; El-Bahrawy M; Ashrafian H; Soga T; Pollard PJ
    Cell Rep; 2013 May; 3(5):1440-8. PubMed ID: 23643539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Succinated Proteome of FH-Mutant Tumours.
    Yang M; Ternette N; Su H; Dabiri R; Kessler BM; Adam J; Teh BT; Pollard PJ
    Metabolites; 2014 Aug; 4(3):640-54. PubMed ID: 25105836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.